Adenocarcinoma of the prostate in perspective.
Adenocarcinoma of the prostate is responsible for one of every nine deaths from cancer in Canada. In this review epidemiologic factors are considered and current staging systems are outlined. The American Urological System is recommended for staging because of its ability to reflect changes in the understanding of the biologic behaviour of this neoplasm. The adoption of a quantitative grading scheme is suggested to complement the information obtained from the staging assessment. The routes of spread of this disease, along with the procedures used to assess metastatic involvement, are described. Immunologic methods for the analysis of prostatic acid phosphatase have been shown to be superior to the enzymatic methods previously used, and the role of the new techniques is discussed. Emphasis is placed on radiotherapy and endocrine therapy for the treatment of this neoplasm, and the concept of withholding endocrine therapy until symptoms appear is discussed. Potential future developments in this field are considered.
D000135:Acid Phosphatase / Q000097:blood; D000230:Adenocarcinoma / Q000628:therapy; D000368:Aged; D001859:Bone Neoplasms / Q000175:diagnosis; D004796:Clinical Enzyme Tests; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006801:Humans; D007158:Immunologic Techniques; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009864:Ontario; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy; D011882:Radiotherapy, High-Energy; D012669:Seminal Vesicles / Q000473:pathology
D004997:Ethinyl Estradiol; D000135:Acid Phosphatase